US President Donald Trump made a sensational announcement regarding the pharmaceutical industry. He declared on social media that starting October 1 , any pharma products manufactured abroad but sold in the US without a domestic production facility will face a 100% tariff. Trump clarified that companies with production plants in the United States will not be affected by this measure.
This move is aimed at encouraging foreign pharmaceutical companies to establish manufacturing units in the US, thereby reducing dependency on imports. Analysts suggest that this decision could significantly impact countries like India, which export a substantial volume of generic drugs and pharmaceuticals to the US market. Companies that rely solely on overseas manufacturing may face increased costs, potentially affecting pricing and supply chains. The announcement has already sparked discussions among global pharma stakeholders about adjusting strategies to comply with the new tariff rules.
This policy signals a major shift in US trade and healthcare strategy.
